The future of cancer treatments
PsiVac’s main target is to be a leading developer of oncolytic viruses in the treatment of cancer, by killing the cancer cells directly and stimulation of the body’s immune response.
Using our patented Adenoviruses we are focused on developing and taking this unique therapy through to human testing phase 1 clinical trials.
Process of Oncolytic viral therapy
PsiVac patented technology uses genetically modified Adenoviruses to target tumours by replicating and killing cancer cells through lysis while predominantly leaving normal cells intact.
Through developing and patenting a portfolio of powerful oncolytic Adenoviruses, able to target and kill solid cancers, while stimulating secondary immunological cancer fighting mechanisms, our goal is to advance our portfolio of treatments into phase 1 clinical trials.
“A new safe, stable and powerful oncolytic virus which offers new hope for cancer patients”
Founder: Ghassan Alusi